Macquarie Group
ORIC icon

Macquarie Group’s Oric Pharmaceuticals ORIC Stock Holding History

Macquarie Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-354
Closed -$2K – 2610
2022
Q1 		$2K Hold
354
– – ﹤0.01% 2614
2021
Q4 		$5K Buy
+354
New +$5.52K ﹤0.01% 2574

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Macquarie Group's ORIC Position: Q2 2022 in Review

Macquarie Group sold out of Oric Pharmaceuticals (ORIC) in Q2 2022, closing a stake of 354 shares — an estimated $2K sold.

Macquarie Group first reported a position in ORIC in Q4 2021 and held it in 2 quarters. The position peaked at $5K in Q4 2021. 83 funds tracked by Wall St. Rank hold ORIC as of Q2 2022.

  • Macquarie Group reported no remaining Oric Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Macquarie Group sold 354 Oric Pharmaceuticals shares in Q2 2022, an estimated $2K.
  • Macquarie Group first reported a position in Oric Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Macquarie Group's Oric Pharmaceuticals position peaked at $5K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2022.

Based on Macquarie Group's 13F filing for Q2 2022, filed 15 Aug 2022.